Meclofenamic acid
Meclodium, Meclomen (meclofenamic acid) is a small molecule pharmaceutical. Meclofenamic acid was first approved as Meclomen on 1982-01-01. The pharmaceutical is active against prostaglandin G/H synthase 2 and prostaglandin G/H synthase 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Meclofenamate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MECLOMEN | Pfizer | N-018006 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| meclofenamate sodium | ANDA | 2021-05-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AG: Fenamates, antiinflammatory and antirheumatic drugs
— M01AG04: Meclofenamic acid
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AA: Antiinflammatory preparations, non-steroids for topical use
— M02AA18: Meclofenamic acid
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | 1 | — | — | 2 |
| Depression | D003863 | F33.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 2 | — | — | — | 2 |
| Smoking | D012907 | EFO_0003768 | F17 | 1 | 1 | — | — | — | 2 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | 1 | 1 | — | — | — | 1 |
| Orthostatic intolerance | D054971 | 1 | 1 | — | — | — | 1 | ||
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
| Macular edema | D008269 | — | 1 | — | — | — | 1 | ||
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | G31.84 | 1 | — | — | — | 1 | 2 | |
| Healthy aging | D000073656 | 1 | — | — | — | — | 1 | ||
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | — | — | — | — | 1 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Magnetic resonance imaging | D008279 | — | — | — | — | 1 | 1 | ||
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | 1 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
| Aids dementia complex | D015526 | EFO_0002608 | — | — | — | — | 1 | 1 | |
| Premature aging | D019588 | Orphanet_79389 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MECLOFENAMIC ACID |
| INN | meclofenamic acid |
| Description | Meclofenamic acid is an aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. It has a role as a non-steroidal anti-inflammatory drug, an antirheumatic drug, an antineoplastic agent, an anticonvulsant, an analgesic, an antipyretic, an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is an aminobenzoic acid, a secondary amino compound and an organochlorine compound. It is a conjugate acid of a meclofenamic acid(1-). |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (anthranilic acid derivatives) and their salts or esters |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl |
Target
Agency Approved
PTGS2
PTGS2
PTGS1
PTGS1
Organism
Homo sapiens
Gene name
PTGS2
Gene synonyms
COX2
NCBI Gene ID
Protein name
prostaglandin G/H synthase 2
Protein synonyms
COX-2, cyclooxygenase 2, cyclooxygenase 2b, Cyclooxygenase-2, PGH synthase 2, PGHS-2, PHS II, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
Uniprot ID
Mouse ortholog
Ptgs2 (19225)
prostaglandin G/H synthase 2 (Q543K3)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,828 documents
View more details
Safety
Black-box Warning
Black-box warning for: Meclofenamate sodium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more